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The methodology consisted of bibliographic research in Pubmed and GoogleScholar databases and immunology journals
including Nature Reviews Immunology, Annual Review of Immunology, Nature Immunology, Trends in Immunology.
Introduction and objectives Methodology
• To understand the immune mechanisms underlying kidney chronic rejection and expose the hallmarks of IS therapy.
• To analyse the methods for ex vivo generation of TolDCs and their therapeutic potential in transplantation.
• To propose an experimental approach to improve TolDC therapy for the treatment of chronic rejection.
The methodology consisted of a bibliographic search in
Pubmed and GoogleScholar databases and immunology
journals including Nature Reviews Immunology, Annual
Review of Immunology, Nature Immunology, Trends in
Immunology.
• The data was extensively analysed and contrasted.
• The main keywords used were, “chronic rejection”,
“kidney transplantation”, “immune tolerance”,
“dendritic cells”, “Tolerogenic dendritic cells”.
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Figure 1. Immunological phases of renal transplant rejection. Donor and recipient DCs present in the donor kidney can be activated
by a pro-inflammatory context induced by renal reperfusion injury or infections. In the lymph node, donor DCs present intact donor MHC and
prime CD4 and CD8 recipient T cells by direct allorecognition, and recipient DCs present processed peptides from MHC molecules in the
context of self-MHC class II to restricted CD4+ T cells. Semi-direct pathway is not shown in this figure. The direct alloresponse takes place
right after transplantation and is the main responsible for acute rejection, while the indirect alloresponse is considered the main pathway
causing chronic rejection. Adapted from [1].
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Tolerogenic dendritic cells (TolDCs) generation and their therapeutic potential in transplantation
Experimental proposal: promoting tolerance to HLA-I peptides to prevent CR Conclusions
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Figure 2. Current immunosuppressive treatment for kidney
transplant rejection and long-term limitations.
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Figure 3. Ex vivo generation of TolDC and molecular mechanisms of tolerance. TGF-b: Tumour Growth Factor b, VITD3: Vitamin D3, PGE2: Prostaglandin-E2,
Dex: Dexamethasone, IDO: Indoleamine 2-3 dyoxigenase 1, Dex: NFKb: Nuclear Factor kb, MHC: Major Histocompatibility Complex, PD-L1: Programmed Death-Ligand 1.
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Kidney transplantation (KT) is nowadays a routine procedure for people with end-stage renal disease. Treatment
with immunosuppressive (IS) drugs has significantly decreased acute rejection rates. However, rates of long-
term kidney loss have remained rather constant over the last decades due to the persistence of chronic allograft
injury. Moreover, the lack of specificity of IS drugs renders the recipient susceptible to infections and cancer in the
long-term. In this sense, Tolerogeni Dendritic Cell (TolDC)-based therapy represe ts an i n vative and
promising approach to achieve kidney transplant success through the inducti n of immune tolerance. The
objectives of this review are:
VitD3
Table 1. Ongoing clinical trials using TolDCs for KT.
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Figure 4. Experimental approach to induce
specific tolerance to donor MHC-I. Recipient
TolDC are pulsed with synthetized peptides
corresponding to mismatched regions between
donor and recipient HLA-I. Then HLA-I-pulsed
TolDCs are intravenously injected 1 day before
kidney transplantation. IS therapy is
administered in combination with cell therapy in
order to reduce the risk of early acute rejection.
• TolDC have demonstrated their therapeutic potential in
transplantation, but we are still at the early beginnings of a
highly promising therapy.
• Safe and efficient TolDC therapy would highly reduce the
dependence on IS drugs, thus minimizing the incidence of
infections and malignancies and improving long-term kidney
graft survival.
• The main limitation of TolDC therapy is the lack of consensus
regarding the optimal protocol for ex vivo generation. Further
analysis of TolDC obtention protocols and mechanisms of
tolerance will improve the potential of TolDC in transplantation.
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